Advertisement

Pharmacological Agents as Tools in Psychiatric Research

  • Samuel Gershon
  • Burton Angrist
  • Baron Shopsin

Abstract

We thought we might approach this problem by exploring the effects of pharmacologically active agents as tools in modifying behavior in the different disease states, in the hope that this might resolve questions of psychoses as either a continuum or as separate and distinct disorders. Secondly - examine these findings in regard to current theories of psychoses.

Keywords

Dopamine Receptor Schizophrenic Patient Manic Episode Auditory Hallucination Organophosphorus Insecticide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anden, N.D., Corrodi, H., Fuxe, K.: Turnover studies using synthesis inhibition. In: Metabolism of amines in the brain, G. Hopper, ed. Macmillan, New York, pp. 38–47, 1969.Google Scholar
  2. 2.
    Angrist, B.M., Gershon, S.: The phenomenology of experimentally-induced amphetamine psychosis: Preliminary Observations. Biol. Psychiat. 2. pp. 95–107, 1970.PubMedGoogle Scholar
  3. 3.
    Angrist, B., Sathananthan, G., and Gershon, S.: Behavioral effects of 1-DOPA in schizophrenic patients. Psycho-pharmacologia 31: 1–2, 1973.CrossRefGoogle Scholar
  4. 4.
    Angrist, B.M., Sathananthan, G., Wilk, S., and Gershon, S.: Behavioral and biochemical effects of 1-DOPA in psychiatric patients. In: Frontiers in Catecholamine Research ed. by E. Usdin and S. Snyder, Pergamon, Oxford, PP.991–994.,1973.Google Scholar
  5. 5.
    Angrist, B.M., and Gershon, S.: The phenomenology of experimentally-induced amphetamine psychosis. Preliminary Observations. Biol. Psychiat. 2: 95–107, 1970.PubMedGoogle Scholar
  6. 6.
    Angrist, B., Gershon, S.: Dopamine and psychotic states: Preliminary remarks, In: Advances in Biochemical Psychopharmacology, Vol. 12, edited by E. Usdin, Raven Press, New York. pp. 211–219, 1974.Google Scholar
  7. 7.
    Angrist, B.M., Shopsin, B., and Gershon, S.: The comparative psychotomimetic effects of stereoisomers of amphetamine. Nature, 234: 152–153, 1971.PubMedCrossRefGoogle Scholar
  8. 8.
    Angrist, B.M., Thompson, H., Shopsin, B., and Gershon, S.: Clinical studies with dopamine receptor stimulants. Psychopharmacologia (Berl.) 44: 273–280, 1975.CrossRefGoogle Scholar
  9. 9.
    Araki, I., Ito, M., Kostyuk, P., Oscarsson, O., and Oshima, I.: The effects of alkaline cations on the responses of cat spinal neurons and their removal from the cell. Proc. R. Soc. Lond. (Biol.), 162: 319, 1965.CrossRefGoogle Scholar
  10. 10.
    Aronoff, M.S., and Epstein, R.S.: Lithium failure in mania: A clinical study. Annual Mtg. of American Psychiatric Association, Bal Harbor, Florida. 1969.Google Scholar
  11. 11.
    Baldessarini, R.J., and Stephens, J.H.: Lithium carbonate for affective disorders. Arch. Gen. Psychiatry, 22: 72, 1970.PubMedCrossRefGoogle Scholar
  12. 12.
    Berlet, H.H., Matsumoto, K., Pscheidt, G.R., Spaide, J., Bull, C, and Himwich, H.E.: Biochemical correlates of behavior in schizophrenic patients. Arch. Gen. Psychiatry, 13: 521–531, 1970.CrossRefGoogle Scholar
  13. 13.
    Brogden, R.N., Spieght, T.M., and Avery, G.S.: Levodopa: A review of pharmacological properties and therapeutic uses with particular reference to Parkinson’s disease. Drugs. 2: 257–408, 1971.CrossRefGoogle Scholar
  14. 14.
    Brune, G.G., Pscheidt, G.R., and Himwich, H.E.: Different responses of urinary tryptamine and of total catecholamines during treatment with reserpine and iscarboxazid in schizophrenic patients. Int. J. Neuropharmacol. 2: 17–23, 1963.CrossRefGoogle Scholar
  15. 15.
    Buchsbaum, M., Goodwin, F., Murphy, D.L., and Borge, G.: Average evoked response in affective disorders. Am. J. Psychiatr., 128 (1): 19–25, 1971.PubMedGoogle Scholar
  16. 16.
    Bunney, W.E., Jr., Murphy, D.L., Goodwin, F.K. and Borge, G.: The switch process from depression to mania: Relationship to drugs which alter “brain amines. Lancet, 1: 1022–1027, 1970.PubMedCrossRefGoogle Scholar
  17. 17.
    Chase, T.N.: Clinical studies of dopaminergic mechanisms. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin, ed. Raven Press, New York, pp. 427–434. 1974.Google Scholar
  18. 18.
    Chase, T.N., Shoulson, I.: Dopaminergic mechanisms in patients with extrapyramidal disease. In: Advances in neurology, Vol. 9, D.B. Calne, T.N. Chase and A. Barbeau, eds. Raven Press, New York, pp. 359–366. 1975.Google Scholar
  19. 19.
    Connell, P.H.: Amphetamine Psychosis. Maudsley Monographs No.5 Oxford Univ. Press, London. 1958.Google Scholar
  20. 20.
    Cooper, J.E., Kendall, R.E., Gurland, B.J., Sartorius, N., and Parkas, T.: Cross national study of diagnoses of mental disorders. Am. J. Psychiatry, 125: 21–29,1969.Google Scholar
  21. 21.
    Corrodi, H., Fuxe, K., Ungerstedt, U.: Evidence for a new type of dopamine receptor stimulating agent. J. Pharm. Pharmacol. 23: 989–991, 1971.PubMedCrossRefGoogle Scholar
  22. 22.
    Costall, B., Naylor, R.J.: On the mode of action of apomorphine, Europ. J.,Pharmacol. 21: 350–361, 1973b.Google Scholar
  23. 23.
    Costall, B., Naylor, R.J.: Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical effect? Psychopharmacologia (Berl.) 32: 161–170. 1973a.CrossRefGoogle Scholar
  24. 24.
    Cotzias, G.C.: Levodopa, manganese and degenerations of the brain, harvey society lectures. Delivered 1972 under the auspices of the Harvey Society Series 68, pp. 115–147, New York, Academic Press. 1974.Google Scholar
  25. 25.
    Creese, I.: Behavioral evidence of dopamine receptor stimulation “by piribedil (ET-495) and its metabolite S 584. Europ. J. Pharmacol. 28: 55–58, 1974.CrossRefGoogle Scholar
  26. 26.
    Davis, J.M. and Janowsky, D. S.: Amphetamine and methylphenidate psychosis. In: Frontiers in Catecholamine Research Pergamon, Oxford, pp. 977–981, 1973.Google Scholar
  27. 27.
    Duby, S.E., Cotzias, G.C., Papayasiliou, P.S., Lawrence, W.H.: Injected apomorphine and orally administered levodopa in Parkinsonism. Arch. Neurol. (Chic). 27: 474–480. 1972.CrossRefGoogle Scholar
  28. 28.
    Dunkley, B., Sanghvi. I., Friedman, E., Gershon, S.: Comparison of behavioral and cardiovascular effects of 1-DOPA and 5-HTP in conscious dogs. Psychopharmacologia (Berl.) 26: 161–172, 1972.CrossRefGoogle Scholar
  29. 29.
    Ellinwood, E.H., Jr., Sudilowsky, A., Nelson, L.: Behavioral analysis of chronic amphetamine intoxication. Biol. Psychiat. 4: 215–230, 1972.PubMedGoogle Scholar
  30. 30.
    Ernst, A.M.: Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologia (Berl.) 10: 316–323, 1967.CrossRefGoogle Scholar
  31. 31.
    Everett, G.M., Borcherding, J.W.: 1-DOPA: Effect on concentration of dopamine, norepinephrine, and serotonin in brains of mice. Science, 168: 849–850, 1970.PubMedCrossRefGoogle Scholar
  32. 32.
    Feldman, P.E.: The treatment of anergic schizophrenia with imipramine. J. Clin., Exp. Psychopath., 20: 235, 1959Google Scholar
  33. 33.
    Fram, D.H., Murphy, D.L., Goodwin, F.K., Keith, H., Brodie, H., Bunney, W.E., Jr. and Snyder, F.: 1-DOPA and sleep in depressed patients. Psychophysiology 7: 316–317, 1970.Google Scholar
  34. 34.
    Friedman, E., Gershon, S.: 1-DOPA: Centrally mediated emission of seminal fluid in male rats. Life Sci., 11: 435–440, 1972.CrossRefGoogle Scholar
  35. 35.
    Fries, H.: Experience with lithium carbonate treatment at a psychiatric department in the period 1964-1967. Acta Psychiatr. Scand. (Suppl), 207: 41, 1969.CrossRefGoogle Scholar
  36. 36.
    Fuxe, K., Agnate, L.F., Corrodi, H., Everitt, B.J., Hokfelt, T. Lofstrom, J., Ungerstedt, U.: Action of dopamine receptor agonists in forebrain and hypothalamus: Rotational behavior, ovulation and dopamine turnover. In: Advances in neurology, Vol. 9, D.B. Calne, T.N. Chase, and A. Barbeau, eds.. Raven Press, New York, pp. 223–242, 1975.Google Scholar
  37. 37.
    Garratini, S., Barreggi, S., Marc, Y., Calderini, G., Marsella, P.L.: Effects of pirobedil on noradrenaline and MOPEGSO4 levels in the rat brain. Europ. J. Pharmacol. 28: 214–2l6Google Scholar
  38. 38.
    Gershon, S., Holmberg, G., Mattson, E., and Mattson, N.: Imipramine hydrochloride. Arch. Gen. Psychiatry. 6: 96–101. 1962.PubMedCrossRefGoogle Scholar
  39. 39.
    Gershon, S., and Shaw, F.H.: Psychiatric sequelae of chronic exposure to organophosphorus insecticides. Lancet, 1: 1371–1374, 1961.PubMedCrossRefGoogle Scholar
  40. 40.
    Glessinger, B.: Evaluation of lithium in treatment of psychotic excitement. Med. J. Aust. 41: 277, 1954.Google Scholar
  41. 41.
    Goldberg, L.I.: Comparison of putative dopamine receptors in blood vessels and the central nervous system. In: Advances in neurology, Vol. 9, D.B. Calne, T.N. Chase, and A. Barbeau, Eds. Raven Press, New York, pp. 53–56 1975.Google Scholar
  42. 42.
    Goldstein, M., Battista, A.F., Ohmoto, T., Anagnoste, B., Fuxe, K.: Tremor and involuntary movements in monkeys: Effects of 1-DOPA and of a dopamine receptor stimulating agent. Science, 179: 816–817, 1973.PubMedCrossRefGoogle Scholar
  43. 43.
    Goldner, R.D.: Control of minor sexual compulsions with Imipramine and amine oxidase regulators. Third World Congr. Psychiatry, 2: 1155, 196l.Google Scholar
  44. 44.
    Goodwin, F.K.: Behavioral effects of 1-DOPA in man. In: Psychiatric Complications of Medical Drugs, Ed. by R.I. Shader, Raven Press, New York, pp. 149–174, 1972.Google Scholar
  45. 45.
    Goodwin, F.K., Murphy, D.L., Brodie, H.K.H. and Bunney, W.E., Jr.: 1-Dopa, catecholamines and behavior: A clinical and biochemical study in depressed patients. Biol. Psychiatry, 2: 341–366, 1970.PubMedGoogle Scholar
  46. 46.
    Greenblatt, M., Grosser, G.H., and Wechsler, H.: A comparative study of selected antidepressant medications and EST. Am. J. Psychiatry, 119: 144–153, 1962.PubMedGoogle Scholar
  47. 47.
    Greenfield, I., Zuger, M., Bleak, R.M., and Bakal, S.F.: Lithium chloride intoxication. New York State J. Med. 50: 549, 1950.Google Scholar
  48. 48.
    Griffith, J.J., Cavanaugh, J.H., and Oates, J.A.: Psychosis induced by the administration of d-amphetamine to human volunteers. In: Psychotomimetic Drugs, edited by D.H. Efron, Raven Press, New York, p. 28, 1970.Google Scholar
  49. 49.
    Grob, D., Harvey, A.M., Langworthy, O.R., and Lilienthal, J.R., Jr.: The administration of di-isopropyl fluorophosphate (DFP) to man. III. Effect on the central nervous system with special reference to the electrical activity of the “brain. Johns Hopkins Med. J., 81: 217, 1947.Google Scholar
  50. 50.
    Hartigan, G.P.: The use of lithium salts in affective disorders. Br. J. Psychiatry, 109: 810, 1963.PubMedCrossRefGoogle Scholar
  51. 51.
    Janowsky, D.S., Davis, J.M.: Dopamine, psychomotor stimulants and schizophrenia: Effects of methylphenidate and the stereoisomers of amphetamine in schizophrenics. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin, ed.Raven Press, New York, pp. 317–323, 1974.Google Scholar
  52. 52.
    Johnson, G., Gershon, S., and Hekimian, L.J.: Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: An interim report. Compr. Psychiatry, 9: 563, 1968.PubMedCrossRefGoogle Scholar
  53. 53.
    Johnson, G., Hekimian, L., and Gershon, S.: Differential drug responsiveness in psychiatric subjects. 8th Annual ACNP Mtg., San Diego, California. 1970.Google Scholar
  54. 54.
    Karobath, M., Diaz, J.L., Huttunen, M.O.: The effect of 1-DOPA on the concentrations of tryptophan, tyrosine, and serotonin in rat brain. Europ. J. Pharmacol. 4: 393–396. 1971.CrossRefGoogle Scholar
  55. 55.
    Klein, D.F.: Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia, 5: 397, 1964.PubMedCrossRefGoogle Scholar
  56. 56.
    Kuhn, R.: Uber die Behandlung depressiver Zustande mit einem Iminobenzyldervat. Schweiz. Med. Wochenschr. 87: 1135, 1957.PubMedGoogle Scholar
  57. 57.
    Kuhn, R.: The treatment of depressive states with G-22355. Am. J. Psychiatry, 115–459, 1958.Google Scholar
  58. 58.
    Lehmann, H.E., and Ban, T.A.: Clinical use of other antipsychotic agents. In: Principles of Psychopharmacology, edited by W.G. Clark and J. del Giudice, Academic Press, New York, p. 621. 1970.Google Scholar
  59. 59.
    Leiberman, A., LE Brun, Y., Dinkar, B., Zolfaghari, M.: The use of dopaminergic receptor stimulating agent (Piribedil, ET-495) in Parkinson’s disease. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin ed.Raven Press, New York, pp. 415–425Google Scholar
  60. 60.
    Leyberg, J.T., and Denmark, J.C.: The treatment of depressive states with Imipramine hydrochloride. Br. J. Psychiat. 105: 1123, 1959.CrossRefGoogle Scholar
  61. 61.
    Lewander, T: Effect of chronic-treatment with central stimu-lants on brain monoamines and some behavioral and physiological functions in rats, guinea pigs and rabbits. In: Advances in Biochemical Psychopharmacology Vol. 12 edited by E. Usdin,Raven Press, New York, pp. 221–239, 1974.Google Scholar
  62. 62.
    Lewander, T.: Effect of chronic-treatment with central stimulants on brain monoamines and some behavioral and physiological functions in rats, guinea pigs and rabbits. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin, ed.,Raven Press, New York, pp. 221–239, 1974.Google Scholar
  63. 63.
    Maj J., Pawlowski, L: The hypothermic effect of 1-DOPA in the rat. Life Sci. 13: 141–149, 1973.PubMedCrossRefGoogle Scholar
  64. 64.
    Mayfield, D., and Brown, R.G.: The clinical laboratory and electroencephalographic effects of lithium. J. Psychiat. Res. 4: 207, 1966.PubMedCrossRefGoogle Scholar
  65. 65.
    Moracci, E.: AZ ione di alcuni sali applicati direttamente sui centri corticali sensitivo-Motori del cane. Arch. Fisiol., 29: 487, 1931.Google Scholar
  66. 66.
    Murphy, D.L., Brodie, H.K.H., Goodwin, F.K., and Bunney, W.E. Jr.: 1-DOPA: Regular induction of hypomania in bipolar manic-depressive patients. Nature. 229: 135–136, 1971.PubMedCrossRefGoogle Scholar
  67. 67.
    Nymark, M.: Apomorphine provoked stereotypy in the dog. Psychopharmacologia (Berl.) 26: 361–368, 1972.PubMedCrossRefGoogle Scholar
  68. 68.
    Paul, M.I., Cramer, H., and Bunney, W.E. Jr.: Urinary cyclic AMP in the switch process from depression to mania. Science, 171: 300–313., 1971.Google Scholar
  69. 69.
    Pfeiffer, C.Z., Singh, M., and Goldstein, L.: Single dose-effect relationship of lithium on the electrical activity of cerebral cortex and of the heart. J. Clin. Pharmacol., 9: 298, 1969.Google Scholar
  70. 70.
    Pilkington, T.L.: A report on “Tofranil” in mental deficiency. Am. J. Ment. Defic., 66: 729, 1962.PubMedGoogle Scholar
  71. 71.
    Pollack, B.: Clinical findings in the use of Tofranil in depressive and other psychiatric states. Am. J. Psychiatry, 116: 312, 1959.PubMedGoogle Scholar
  72. 72.
    Pollin, W., Cordon, P.V. and Kety, S.S.: Effects of amino acid feedings in schizophrenic patients treated with ipro-niazid. Science, 133: 104–105, 1961.PubMedCrossRefGoogle Scholar
  73. 73.
    Randrup. A., Munkvad, I.: Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia (Berl.) 11, 300–310, 1967.CrossRefGoogle Scholar
  74. 74.
    Rees, L., and Benaim, S.: An evaluation of iproniazid in the treatment of depression. Br. J. Psychiatry, 106: 193–202, 1960.CrossRefGoogle Scholar
  75. 75.
    Rochford, J.M., Detre, T., Tucker, G.J., Harrow, M.: Neuropsychological impairments in functional psychiatric disease. Arch. Gen. Psychiatry, 22: 114, 1970.PubMedCrossRefGoogle Scholar
  76. 76.
    Rotrosen, J., Wallach, M.B., Angrist, B., Gershon, S.: Antagonism of apomorphine induced stereotypy and emesis in dogs by thioridazine, haloperidol, and pimozide. Psychopharmacologia (Berl.) 26: 185–194, 1972.CrossRefGoogle Scholar
  77. 77.
    Rountree, D.W., Nevin, S., and Wilson, A.: The effects of diisoprophylfluorophosphonate in schizophrenia and manic depressive psychosis. J. Neurol. Neurosurg. Psychiatry. 13: 47–62, 1950.CrossRefGoogle Scholar
  78. 78.
    Sathananthan, G., Angrist, B.M., and Gershon, S.: Response threshold to 1-DOPA in psychiatric patients. Biol. Psychiatry, 7: 139–149, 1973.PubMedGoogle Scholar
  79. 79.
    Schou, M.: Lithium in psychiatric therapy. Psychopharmacologia, 1: 65, 1959.PubMedCrossRefGoogle Scholar
  80. 80.
    Schou, M., Juel-Nielson, N., Stromgren, E., and Boldby, H.: The treatment of manic psychoses by the administration of lithium salts. J. Neurol. Neurosurg, Psychiatry. 17: 250, 1954.CrossRefGoogle Scholar
  81. 81.
    Schwab, R.S., Amador, L.V., Lettvin, J.Y.: Apomorphine in Parkinson’s disease. Trans. Amer. Neurol. Ass. 76: 251–263, 1951.Google Scholar
  82. 82.
    Shopsin, B., Kim, S.S. and Gershon, S.: A controlled study of lithium vs. chlorpromazine in acute schizophrenics. Brit. J. Psychiatry, 119: 435–440, 1971.Google Scholar
  83. 83.
    Shopsin, B., Johnson, G., and Gershon, S.: Neurotoxicity with lithium: differential drug responsiveness. Int. Pharmacopsychiatry. 1970.Google Scholar
  84. 84.
    Sivadon, P., and Chanoit, P: Clinical experience with lithium treatment of psychomotor excitation. Ann. Medicopsychol. 113: 790, 1955.PubMedGoogle Scholar
  85. 85.
    Snyder, S.H.: Amphetamine psychosis: a “model” schizophrenia mediated by catecholamines. Am. J. Psychiatry, 130: 61–67, 1973.PubMedGoogle Scholar
  86. 86.
    Spensley, J. and Rockwell, D.A.: Psychosis during methylpheni-date abuse. New Engl. J. Med. 286: 880–881, 1972.PubMedCrossRefGoogle Scholar
  87. 87.
    Spring, G.K., Schweid, D., Gray, C, Steinberg, J. and Harwitz, M.: A double blind comparison of lithium and chlorpromazine in the treatment of manic states. Am. J. Psychiatry, 126: 1306, 1970.PubMedGoogle Scholar
  88. 88.
    Strian, F., Michler, E., Benkert, P.: Tremor inhibition in Parkinson syndrome after apomorphine administration under 1-DOPA and decarboxylase inhibitor basic therapy. Pharmakopsychiat.5: 198–205, 1972.CrossRefGoogle Scholar
  89. 89.
    Turner, W. and Merlis, S.:A clinical trial of pargyline and and 1-DOPA in psychotic subjects. Dis. Nerv. Syst. 24: 538–541, 1964.Google Scholar
  90. 90.
    Ungerstedt, U.: Postsynaptic supersensitivity after 6-hydroxy-dopamine-induced degeneration of the nigrotriatal dopamine system. Acta. Physiol. Scand., Suppl. 367: 69–93, 1971.Google Scholar
  91. 91.
    VAN Beek, M.C., Timmerman, H.: Some benzhydryl derivatives as central dopamine receptor stimulating agents. J. Pharm. Pharmacol. 26: 57–58, 1974.PubMedCrossRefGoogle Scholar
  92. 92.
    Wallach, M.B.: Drug-induced stereotyped behaviour: similarities and differences. In: Advances in Biochemical Psycho-pharmacology, Vol. 12, edited by E. Usdin,Raven Press, New York, pp. 241–260, 1974.Google Scholar
  93. 93.
    Walters, J., Bunney, B.S., Roth, R.H.: Piribedil and apomor-phine: Pre-and postsynaptic effects on dopamine synthesis and neuronal activity. In: Advances in neurology, Vol. 9, D.B. Calne, T.N. Chase and A. Barbeau eds.,Raven Press, New York, pp. 273–284, 1975.Google Scholar
  94. 94.
    Willner, J.H., Samach, M., Angrist, B.M., Wallach, M.B., Gershon, S.: Drug-induced stereotyped behavior and its antagonism in dogs. Commun. Behav. Biol. 5: 135–141. 1970.Google Scholar
  95. 95.
    Wyatt, R.J., Chase, T.N. and Englemen, K.: Effect of 1-DOPA on the sleep of man. Nature, 228: 999–1001, 1970.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1977

Authors and Affiliations

  • Samuel Gershon
    • 1
  • Burton Angrist
    • 1
  • Baron Shopsin
    • 1
  1. 1.Neuropsychopharmacology Research Unit Department of PsychiatryNew York University Medical CenterNew YorkUSA

Personalised recommendations